Bortezomib alleviates myocardial ischemia reperfusion injury via enhancing of Nrf2/HO-1 signaling pathway
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 556, 207-214
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 28 references indexed in Scilit:
- Role of the Ubiquitin Proteasome System in the HeartCirculation Research, 2013
- Genetically Induced Moderate Inhibition of the Proteasome in Cardiomyocytes Exacerbates Myocardial Ischemia-Reperfusion Injury in MiceCirculation Research, 2012
- A Murine Closed-chest Model of Myocardial Ischemia and ReperfusionJournal of Visualized Experiments, 2012
- Cardiotoxicity of the Anticancer Therapeutic Agent BortezomibThe American Journal of Pathology, 2010
- Protection of vascular cells from oxidative stress by proteasome inhibition depends on Nrf2Cardiovascular Research, 2009
- Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitorsCardiovascular Research, 2009
- Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotectionCardiovascular Research, 2009
- Inhibitory kappa B kinase-β is a target for specific nuclear factor kappa B-mediated delayed cardioprotectionThe Journal of Thoracic and Cardiovascular Surgery, 2008
- Proteasome Inhibition Attenuates Infarct Size and Preserves Cardiac Function in a Murine Model of Myocardial Ischemia-Reperfusion InjuryThe Annals of Thoracic Surgery, 2007
- Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2–dependent mechanismsNature Medicine, 2005